Takeda Pharmaceutical Q3 Earnings Call Highlights

• Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 third-quarter results that executives said reflected “the spot of Takeda fundamentals,” supported by disciplined outgo absorption arsenic the institution prepares for respective late-stage merchandise launches. Management emphasized that fiscal 2025 is simply a “pivotal year,” with 3 cardinal pipeline assets—oveporexton, rusfertide, and zasocitinib—expected to signifier the adjacent signifier of growth.

Chief Financial Officer Milano Furuta said the institution continues to negociate the “significant impact” from Vyvanse generic erosion, but noted the headwind has been “steadily tapering off” 4th by quarter. For the nine-month period, Takeda posted gross of conscionable implicit JPY 3.4 trillion, down 3.3% twelvemonth implicit twelvemonth (down 2.8% astatine changeless speech rates). Core operating nett was JPY 971.6 billion, down 3.4% twelvemonth implicit year, portion reported operating nett roseate 1.2% to JPY 422.4 billion. Core EPS was JPY 428 and reported EPS was JPY 137.

→ Kinder Morgan’s Natural Gas/Dividend Growth Cycle Still successful Play

• Time to bargain these 3 healthcare companies that raised gross guidance?

Furuta highlighted beardown currency generation, reporting adjusted escaped currency travel of JPY 625.9 cardinal for the period, adjacent aft a $1.2 cardinal upfront outgo to Innovent Biologics made successful December.

Management updated its full-year guidance by revising gross expectations downward astatine changeless speech rates, citing stronger-than-anticipated Vyvanse generic erosion successful the U.S. Furuta said Takeda is “revising lone gross guidance to debased single-digit diminution astatine CER,” portion maintaining full-year guidance for halfway operating nett and halfway EPS owed to ongoing operating disbursal discipline. Based connected revised FX assumptions, Takeda forecast full-year gross of JPY 4.53 trillion, halfway operating nett of JPY 1.15 trillion, and halfway EPS of JPY 486. The institution besides upgraded its adjusted escaped currency travel forecast.

→ Trump Triggers Buying Opportunity successful UnitedHealth Group

• Price Growth & Yield: For That Magical Combo, Leave the U.S.

Takeda’s maturation and motorboat products represented much than 50% of full gross and grew 6.7% astatine changeless speech rates twelvemonth to date, improving from the 5% maturation complaint reported successful the archetypal 2 quarters.

• Gastrointestinal (GI): Entyvio grew 7.4% astatine changeless speech rates. Furuta said the third-quarter maturation was “particularly strong,” successful portion owed to a prior-year one-time gross-to-net impact. Management cited Entyvio Pen arsenic a cardinal operator and said it is present connected the formulary with each 3 ample pharmacy payment managers, with commercialized sum supra 80%.

• Rare diseases: Takhzyro maturation slowed to 2.4% astatine changeless speech rates. Executives attributed unit successful the U.S. to caller competitors, partially offset by planetary uptake. CEO-elect Julie Kim besides said the marketplace is maturing with precocious diagnosis and prophylaxis penetration, and noted an interaction from Medicare Part D redesign.

• Plasma-derived therapies (PDT): Furuta said gross maturation improved versus the archetypal fractional but pointed to headwinds successful albumin. Albumin returned to 1.3% maturation but was slower than expected owed to softening request successful China and proviso reallocation effects. Kim said China’s utilization guidelines person impacted request and that maturation could instrumentality clip to return. Management said immunoglobulin (IG) grew 4.3% twelvemonth to date, driven by double-digit maturation successful subcutaneous IG; IVIG was impacted by Medicare Part D redesign, which Takeda expects to normalize successful the 4th quarter.

• Vaccines: Qdenga maturation accelerated to 22.1%, driven chiefly by Brazil.